Posters

Early effects of intravitreal injection of Ozurdex® implant in patients with naïve diabetic macular edema: Preliminary results

Poster Details

First Author: N.Romanic SPAIN

Co Author(s):    S. Gomez Sanchez                             

Abstract Details



Purpose:

To analyse the effects on visual acuity and central retinal thickness two months after intravitreal injection of dexamethasone implant as a first-line treatment of diabetic macular edema (DME)

Setting:

Twelve eyes of 8 patients diagnosed of diffuse or multifocal DME, which had not been previously treated, received a single intravitreal injection of Ozurdex® implant.

Methods:

Best corrected visual acuity (BCVA) was assessed through early treatment diabetic retinopathy study (ETDRS) tables in baseline and two months after injection evaluations. As well, optical coherence tomography (OCT) with Topcon 3D OCT-2000 (Topcon Medical Systems. Tokyo, Japan) was performed for measurement of macular thickness in both evaluations. Data were analysed by Wilcoxon Signed-Rank Test. A P-value <0.05 was considered statistically significant.

Results:

The mean age of the patients included in the study was 69.54±6.27 years. There were 8 men (66.7%) and 4 women (33.3%) included. Mean glycosylated haemoglobin was 8.13±0.98%. Before the injection of the intravitreal dexamethasone implant, the medial BCVA was 50±18.6 letters, and the average thickness of the retina was 524.3±155.4µm. Two months after the intravitreal injection of Ozurdex® implant, BCVA significantly improved 9.6±6.2 letters (p=0.00512), and central foveal thickness significantly decreased 236.3±179.9µm (p=0.00596).

Conclusions:

There is evidence from randomized clinical trials demonstrating the efficacy and safety of Ozurdex® in improving BCVA and reducing macular thickness in patients with DME, and this is achievable with a reduced intravitreal injection frequency compared with anti-VEGF therapy. Ozurdex® is mainly used as a second-line treatment in patients with DME who do not respond to consecutive anti-VEGF treatment, but it may be considered as a first-line treatment in some situations.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy